Literature DB >> 18990585

Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study.

Vincent Launay-Vacher1, Jean-Philippe Spano, Nicolas Janus, Joseph Gligorov, Isabelle Ray-Coquard, Stéphane Oudard, Xavier Pourrat, Jean-François Morere, Philippe Beuzeboc, Gilbert Deray.   

Abstract

The Renal Insufficiency and Anticancer Medications (IRMA) study is a French national, observational study which demonstrated the high prevalence of abnormal renal function in a population of 4684 solid tumor patients. Among them, 50-60% had decreased renal function, and 80% were treated with anticancer drugs that either necessitated dosage adjustment in case of renal insufficiency (RI) or were potentially nephrotoxic drugs. Since elderly patients are well-known to have reduced renal function, either due to physiological aging or their disease/medication history, a subgroup analysis of this particular population of patients was performed. In 1553 IRMA patients whose age was > or =65 years, the prevalence of RI was very high in spite of normal serum creatinine values in most cases. Anticancer drugs used may be nephrotoxic or need dosage adjustment in a high number of cases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18990585     DOI: 10.1016/j.critrevonc.2008.09.012

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  17 in total

Review 1.  Adjuvant chemotherapy for breast cancer in older women: emerging evidence to aid in decision making.

Authors:  Gretchen Kimmick
Journal:  Curr Treat Options Oncol       Date:  2011-09

2.  Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.

Authors:  Stuart M Lichtman; Constance T Cirrincione; Arti Hurria; Aminah Jatoi; Maria Theodoulou; Antonio C Wolff; Julie Gralow; Daniel E Morganstern; Gustav Magrinat; Harvey Jay Cohen; Hyman B Muss
Journal:  J Clin Oncol       Date:  2016-01-11       Impact factor: 44.544

Review 3.  Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer.

Authors:  Stephanie Strobl; Kerstin Wimmer; Ruth Exner; Yelena Devyatko; Michael Bolliger; Florian Fitzal; Michael Gnant
Journal:  Curr Treat Options Oncol       Date:  2018-03-12

4.  Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer.

Authors:  Giulia Russo; Giovanni Cioffi; Andrea Di Lenarda; Fausto Tuccia; Daniella Bovelli; Giuseppe Di Tano; Gianfranco Alunni; Stefania Gori; Pompilio Faggiano; Luigi Tarantini
Journal:  Intern Emerg Med       Date:  2012-06-20       Impact factor: 3.397

5.  Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid.

Authors:  Matti Aapro; Fred Saad
Journal:  Ther Adv Urol       Date:  2012-04

Review 6.  Bladder cancer.

Authors:  David J Gallagher; Matthew I Milowsky
Journal:  Curr Treat Options Oncol       Date:  2009-08

7.  Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial.

Authors:  Diana Crivellari; Kathryn P Gray; Silvia Dellapasqua; Fabio Puglisi; Karin Ribi; Karen N Price; István Láng; Lorenzo Gianni; Simon Spazzapan; Graziella Pinotti; Jean-Marc Lüthi; Richard D Gelber; Meredith M Regan; Marco Colleoni; Monica Castiglione-Gertsch; Rudolf Maibach; Manuela Rabaglio; Alan S Coates; Aron Goldhirsch
Journal:  Breast       Date:  2013-02-28       Impact factor: 4.380

Review 8.  Malaria prophylaxis in patients with renal impairment: a review.

Authors:  Sabine Amet; Sarah Zimner-Rapuch; Vincent Launay-Vacher; Nicolas Janus; Gilbert Deray
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

9.  Doublet chemotherapy in the elderly patient with ovarian cancer.

Authors:  Min Y Teo; Derek G Power; William P Tew; Stuart M Lichtman
Journal:  Oncologist       Date:  2012-08-22

Review 10.  Toxicity of Cancer Therapies in Older Patients.

Authors:  Olivia Le Saux; Claire Falandry
Journal:  Curr Oncol Rep       Date:  2018-06-13       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.